Literature DB >> 9446632

Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas.

A Carbone1, G Gaidano, A Gloghini, L M Larocca, D Capello, V Canzonieri, A Antinori, U Tirelli, B Falini, R Dalla-Favera.   

Abstract

This study was aimed at defining the histogenesis of the pathologic spectrum of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas (AIDS-NHL), including AIDS-related small noncleaved cell lymphoma (AIDS-SNCCL), AIDS-related large noncleaved cell lymphoma (AIDS-LNCCL), AIDS-related large cell immunoblastic lymphoma plasmacytoid (AIDS-IBLP), and AIDS-related primary effusion lymphoma (AIDS-PEL). Forty-six cases of AIDS-NHL were investigated for the expression pattern of BCL-6, a protein specifically expressed by germinal center (GC) B-cells, and CD138/syndecan-1 (syn-1), a marker of post-GC B-cell differentiation. Expression of BCL-6 and syn-1 segregated two major phenotypic patterns among AIDS-NHL: (1) the BCL-6+/syn-1- pattern associated with AIDS-SNCCL and AIDS-LNCCL; (2) the BCL-6-/syn-1+ pattern associated with AIDS-IBLP and AIDS-PEL. Among systemic AIDS-NHL infected by Epstein-Barr virus (EBV), expression of the EBV-encoded latent membrane protein-1 (LMP-1) preferentially associated with the BCL-6-/syn-1+ profile. Analysis of nonneoplastic lymph nodes showed that the two phenotypic patterns detected in AIDS-NHL correspond to physiologic stages of B-cell development, i.e., GC B-cells (BCL-6+/syn-1-) and preterminally differentiated post-GC B-cells (BCL-6-/syn-1+). Thus, BCL-6+/syn-1- AIDS-NHL reflects a GC stage of differentiation, whereas AIDS-NHL which are BCL-6-/syn-1+, and LMP-1+ when infected by EBV, derive from B cells that have entered post-GC plasmacell differentiation. These findings are relevant for the pathogenesis and differential diagnosis of AIDS-NHL.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9446632

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues.

Authors:  M Teitell; M A Damore; G G Sulur; D E Turner; M H Stern; J W Said; C T Denny; R Wall
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas.

Authors:  Xing Wang; Zhiping Li; Akira Naganuma; B Hilda Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-29       Impact factor: 11.205

3.  Comparative analysis of signal transduction by CD40 and the Epstein-Barr virus oncoprotein LMP1 in vivo.

Authors:  Dimitris Panagopoulos; Panayiotis Victoratos; Maria Alexiou; George Kollias; George Mosialos
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 4.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

Review 5.  EBV Persistence--Introducing the Virus.

Authors:  David A Thorley-Lawson
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

6.  Epstein-Barr virus represses the FoxO1 transcription factor through latent membrane protein 1 and latent membrane protein 2A.

Authors:  Angharad M Shore; Paul C White; Rosaline C-Y Hui; Abdelkader Essafi; Eric W-F Lam; Martin Rowe; Paul Brennan
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

7.  Latent membrane protein 1 deletion mutants accumulate in reed-sternberg cells of human immunodeficiency virus-related Hodgkin's lymphoma.

Authors:  Massimo Guidoboni; Maurilio Ponzoni; Laura Caggiari; Antonia A Lettini; Luca Vago; Valli De Re; Annunziata Gloghini; Paola Zancai; Antonino Carbone; Mauro Boiocchi; Riccardo Dolcetti
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

Review 8.  Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients.

Authors:  Ethel Cesarman
Journal:  Cancer Lett       Date:  2011-04-13       Impact factor: 8.679

9.  Epstein-barr virus-induced changes in B-lymphocyte gene expression.

Authors:  Kara L Carter; Ellen Cahir-McFarland; Elliott Kieff
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Determinants of the establishment of human immunodeficiency virus type 1 latency.

Authors:  Alexandra Duverger; Jennifer Jones; Jori May; Frederic Bibollet-Ruche; Frederic A Wagner; Randall Q Cron; Olaf Kutsch
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.